Telix Pharmaceuticals Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TLPPF | LGND | IDYA | NRIX | RCUS | INBX | |
|---|---|---|---|---|---|---|
| Market cap | 3.47B | 5.89B | 3.17B | 2.67B | 2.78B | 1.32B |
| P/E (TTM) | 102.0 | 31.1 | — | 10.0 | — | — |
| Forward P/E | — | 24.7 | -7.9 | -19.1 | -7.1 | -10.3 |
| Price/book | 7.1 | 6.1 | 2.6 | 2.8 | 6.1 | -24.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −0.49% | +58.26% | +7.67% | +135.03% | +26.62% | +135.03% |
| Today | 0.00% | −0.99% | −2.95% | −2.12% | −3.07% | −0.74% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TLPPF news ›Why Is Telix Pharmaceuticals (ASX:TLX) Back in Focus?
Telix said earlier this month that Pixclara had reached its initial patients at hospitals in Cleveland and Indianapolis, with doses supplied through a radiopharmacy network operated by PharmaLogic. The announcement followed the United…
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Profound is developing imaging integration for a future software release, with potential benefits for patient selection and treatment planning. Profound is also developing image-fusion capabilities for a planned future Treatment Delivery…
News from Telix Pharmaceuticals Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
news News from Telix Pharmaceuticals Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. 16:00 ET…
Telix Pharmaceuticals: Merger Bodes Well For Long-Term Plan
Telix Pharmaceuticals advances its imaging and therapeutic portfolio, highlighted by Pixclara's FDA approval & rapid commercial rollout. Read more on TLX stock. - Telix Pharmaceuticals advances its imaging and therapeutic portfolio,…
UBS thinks Telix Pharmaceuticals shares will go how high?
Good news out of the US has led to a share price target upgrade. Mining and energy Biotechnology Personal finance Wine Education Bachelor of Arts, Graduate Diploma in Journalism, Graduate Certificate in Applied Finance, AICD Company…
Telix Pharmaceuticals shares jump on first US patient dosing for brain cancer imaging
The news: Shares in Telix Pharmaceuticals jumped in afternoon trade after the cancer diagnostic specialist announced that the first sets of patients have been dosed with its newly FDA approved brain cancer (glioma) imaging agent, Pixclara,…
Telix Pharmaceuticals Limited reports first US Pixclara doses for glioma imaging
PharmaLogic supplied doses to hospitals in Indiana and Ohio; Telix's Oct. 6 launch release gave no Pixclara sales target. Commercial Pixclara dosing reached its first U.S. patients as Telix Pharmaceuticals Limited ASXTLX NASDAQTLX…
Telix Pharmaceuticals Launches US Commercial Availability of Brain Cancer Imaging Drug
marketscreener.com Biotechnology & Medical Research Telix Pharmaceuticals Launches US Commercial Availability of Brain Cancer Imaging Drug Published on 10/06/2026 at 05:26 pm EDT
Why Telix Pharmaceuticals (ASX:TLX) Is Drawing Attention After FDA Fast Track Designation for Its BiPASS Prostate Imaging Program
Top 10 ASX Dividend Stocks for Oct 2026 Download Free Report This article summarises the contents of that announcement, sets out the surrounding sector backdrop, notes risks that the company itself flags, and outlines the next steps…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
kalkinemedia.com6
-
fool.com.au4
-
mugglehead.com2
-
tradingview.com2
-
capitalbrief.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 21 articles, not a forecast.